Tandem Diabetes Care to Announce First Quarter 2023 Financial Results on May 3, 2023

Rhea-AI Summary

Tandem Diabetes Care plans to release its first quarter 2023 results on May 3, 2023, after market close. A conference call will take place at 4:30 PM ET to discuss financial and operating results. Investors can access the live webcast on the company's Investor Center website. The event will provide insights into the company's performance, focusing on innovative diabetes technology products such as the t:slim X2 insulin pump with Control-IQ technology. Tandem Diabetes Care aims to enhance the experience for individuals managing diabetes through its human-centered approach.

Positive

• Anticipated insights from first quarter 2023 financial results.
• Focus on innovative products like the t:slim X2 insulin pump.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2023 results after the financial markets close on Wednesday, May 3, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2023 financial and operating results.

A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. To access the call by phone, please use this link (https://register.vevent.com/register/BI21343b3e346b4b66923ccc4e1bd048e5) and you will be provided with dial-in details, including a personal pin.

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care and Control-IQ are trademarks registered in the U.S. and/or other countries and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and #TandemDiabetes.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005745/en/

Media Contact:

858-255-6388

media@tandemdiabetes.com



Investor Contact:

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.

FAQ

When will Tandem Diabetes Care release its first quarter 2023 results?

Tandem Diabetes Care will release its first quarter 2023 results on May 3, 2023.

What time is the conference call for Tandem Diabetes Care's Q1 2023 results?

The conference call will take place at 4:30 PM ET on May 3, 2023.

How can I access the webcast for Tandem Diabetes Care's earnings call?

The webcast can be accessed on Tandem Diabetes Care's Investor Center website.

What products does Tandem Diabetes Care focus on?

Tandem Diabetes Care focuses on insulin delivery products, notably the t:slim X2 insulin pump with Control-IQ technology.